Adaptive Biotechnologies Corp — Director's Dealing 2020

Jun 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2020-06-08

Reporting Person: BALDO LANCE (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-08	Common Stock	M	2083	$7.80	Acquired	2083	Direct
2020-06-08	Common Stock	S	120	$39.59	Disposed	1963	Direct
2020-06-08	Common Stock	S	1963	$38.99	Disposed	0	Direct
2020-06-09	Common Stock	M	4167	$7.80	Acquired	4167	Direct
2020-06-09	Common Stock	S	4167	$40.00	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-08	Stock Option (Right to Buy)	$7.80	M	2083	Disposed	2029-05-06	Common Stock (2083)	Direct
2020-06-09	Stock Option (Right to Buy)	$7.80	M	4167	Disposed	2029-05-06	Common Stock (4167)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020.

F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.50 to 39.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.50 to 39.43, inclusive.

F4: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested.